Archives

  • 2019-10
  • 2020-03
  • 2020-07
  • 2020-08
  • E-64 br Conflict of interest statement

    2020-08-14


    Conflict of interest statement
    The authors declare that they have no conflict of interest.
    Appendix A. Supplementary data
    References
    [2] Schott AF, Barlow WE, Van Poznak CH, Hayes DF, Moinpour CM, Lew DL, et al. Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 2016; 159(1):87e95.
    [6] Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor E-64 circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10(20):6897e904.
    [7] Calabuig-Farinas S, Jantus-Lewintre E, Herreros-Pomares A, Camps C. Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win? Transl Lung Cancer Res 2016; 5(5):466e82.
    [8] Tan CR, Zhou L, El-Deiry WS. Circulating tumor cells versus circulating tumor DNA in colorectal cancer: pros and cons. Curr Colorectal Cancer Rep 2016;12(3):151e61.
    [9] Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, et al. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. J Hematol Oncol 2017;10(1):100.
    [14] Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of indi-vidual patient data. Lancet Oncol 2014;15(4):406e14.
    [15] Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, et al. Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase III clinical trials. J Clin Oncol 2018; 36(6):572e80.
    [17] O’Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun 2018;9(1):896.
    [19] Shaw JA, Guttery DS, Hills A, Fernandez-Garcia D, Page K, Rosales BM, et al. Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high circulating tumor cell counts. Clin Cancer Res 2017;23(1): 88e96.
    [20] Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61(4): 1659e65.
    [23] Wang JF, Pu X, Zhang X, Chen K, Xi Y, Wang J, et al. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer 2018;124(5):1061e9.
    [24] Kuderer NM, Burton KA, Blau S, Rose AL, Parker S, Lyman GH, et E-64 al. Comparison of 2 commercially available next-generation sequencing platforms in Oncology. JAMA Oncol 2017; 3(7):996e8.
    [25] Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 2018. JCO2017768671.
    [26] Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Arch Pathol Lab Med 2018; 36(16):1631e41.
    [28] Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Dis-cov 2014;4(6):650e61.
    [29] Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti MR, et al. Plasma total cell-free DNA (cfDNA) is a sur-rogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer 2018; 88:1e9.
    [30] Mehra N, Dolling D, Sumanasuriya S, Christova R, Pope L, Carreira S, et al. Plasma cell-free DNA concentration and out-comes from taxane therapy in metastatic castration-resistant prostate cancer from two phase III trials (FIRSTANA and PROSELICA). Eur Urol 2018;74(3):283e91.
    [32] Hsieh CC, Hsu HS, Chang SC, Chen YJ. Circulating cell-free DNA levels could predict oncological outcomes of patients un-dergoing esophagectomy for esophageal squamous cell carci-noma. Int J Mol Sci 2016;17(12).
    [36] Lehner J, Stotzer OJ, Fersching DM, Nagel D, Holdenrieder S. Plasma DNA integrity indicates response to neoadjuvant chemotherapy in patients with locally confined breast cancer. Int J Clin Pharmacol Ther 2013;51(1):59e62.